A detailed history of Assetmark, Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Assetmark, Inc holds 3,445 shares of BCRX stock, worth $26,802. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,445
Previous 3,445 -0.0%
Holding current value
$26,802
Previous $21,000 23.81%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$4.89 - $7.65 $7,310 - $11,436
1,495 Added 76.67%
3,445 $17,000
Q1 2023

May 05, 2023

BUY
$7.94 - $11.84 $3,573 - $5,328
450 Added 30.0%
1,950 $16,000
Q4 2022

Feb 10, 2023

BUY
$10.5 - $14.2 $4,935 - $6,674
470 Added 45.63%
1,500 $17,000
Q3 2022

Nov 01, 2022

BUY
$10.79 - $14.81 $11,113 - $15,254
1,030 New
1,030 $13,000
Q1 2022

May 13, 2022

SELL
$11.56 - $19.76 $1,109 - $1,896
-96 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $1,073 - $1,484
96 New
96 $1,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.